Eskiler, G. G. Et Al. 2018. Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer. Conference on Molecular Analysis for Personalised Therapy (MAP) , (Paris, France).

Eskiler, G. G., Cecener, G., Egeli, Ü., & Tunca, B., (2018). Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer . Conference on Molecular Analysis for Personalised Therapy (MAP), Paris, France

Eskiler, G. Et Al. "Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer," Conference on Molecular Analysis for Personalised Therapy (MAP), Paris, France, 2018

Eskiler, G. G. Et Al. "Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer." Conference on Molecular Analysis for Personalised Therapy (MAP) , Paris, France, 2018

Eskiler, G. G. Et Al. (2018) . "Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer." Conference on Molecular Analysis for Personalised Therapy (MAP) , Paris, France.

@conferencepaper{conferencepaper, author={G. Guney Eskiler Et Al. }, title={Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer}, congress name={Conference on Molecular Analysis for Personalised Therapy (MAP)}, city={Paris}, country={France}, year={2018}}